nach oben

Erschienen in:

01.07.2020 | News item

Health Canada: risk of VTE with tofacitinib and ruxolitinib

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

There is a risk of venous thromboembolic events (VTE) with the use of two Janus kinase (JAK) inhibitors − tofacitinib (Xeljanz/Xeljanz XR) and ruxolitinib (Jakavi), says Health Canada. ¹ …

In Canada, tofacitinib is available by prescription for the treatment of inflammatory diseases (e.g. rheumatoid arthritis, psoriatic arthritis, ulcerative colitis) when other therapies do not work. Ruxolitinib is also available by prescription for the treatment of certain rare blood cancers (e.g. primary myelofibrosis and polycythaemia vera).

Health Canada. Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib), and Jakavi (ruxolitinib) - Janus Kinase (JAK) inhibitors - Health Canada. Internet Document : 18 Jun 2020. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00240

Titel: Health Canada: risk of VTE with tofacitinib and ruxolitinib
Publikationsdatum: 01.07.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-80226-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Health Canada: risk of VTE with tofacitinib and ruxolitinib

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Dexamethasone

Ropivacaine overdose

Naloxone

Arsenic-trioxide/tretinoin

Iohexol

Rivoceranib